JP7386174B2 - Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物 - Google Patents

Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物 Download PDF

Info

Publication number
JP7386174B2
JP7386174B2 JP2020551912A JP2020551912A JP7386174B2 JP 7386174 B2 JP7386174 B2 JP 7386174B2 JP 2020551912 A JP2020551912 A JP 2020551912A JP 2020551912 A JP2020551912 A JP 2020551912A JP 7386174 B2 JP7386174 B2 JP 7386174B2
Authority
JP
Japan
Prior art keywords
cancer
her2
mutations
exon
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020551912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519306A5 (enExample
JP2021519306A (ja
Inventor
ジャクリーン ロビショー
ジョン ブイ． ヘイマッハ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2021519306A publication Critical patent/JP2021519306A/ja
Publication of JP2021519306A5 publication Critical patent/JP2021519306A5/ja
Application granted granted Critical
Publication of JP7386174B2 publication Critical patent/JP7386174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020551912A 2018-03-27 2019-03-27 Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物 Active JP7386174B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862648629P 2018-03-27 2018-03-27
US62/648,629 2018-03-27
US201862688049P 2018-06-21 2018-06-21
US62/688,049 2018-06-21
PCT/US2019/024353 WO2019191279A2 (en) 2018-03-27 2019-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations

Publications (3)

Publication Number Publication Date
JP2021519306A JP2021519306A (ja) 2021-08-10
JP2021519306A5 JP2021519306A5 (enExample) 2022-04-01
JP7386174B2 true JP7386174B2 (ja) 2023-11-24

Family

ID=68060750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551912A Active JP7386174B2 (ja) 2018-03-27 2019-03-27 Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物

Country Status (14)

Country Link
US (1) US20210361655A1 (enExample)
EP (1) EP3773551B1 (enExample)
JP (1) JP7386174B2 (enExample)
KR (1) KR102899689B1 (enExample)
CN (1) CN112088000A (enExample)
AU (1) AU2019243738B2 (enExample)
BR (1) BR112020019251A2 (enExample)
CA (1) CA3094108A1 (enExample)
IL (1) IL277373A (enExample)
MX (1) MX2020010121A (enExample)
PH (1) PH12020551495A1 (enExample)
RU (1) RU2020134932A (enExample)
SG (1) SG11202009498RA (enExample)
WO (1) WO2019191279A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271948B (zh) * 2018-12-21 2024-08-16 得克萨斯大学体系董事会 治疗癌症的联合疗法
AU2020254499A1 (en) * 2019-03-29 2021-10-28 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 insertions
SG11202111120VA (en) * 2019-04-17 2021-11-29 Univ Texas Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529115A (ja) 2007-06-05 2010-08-26 ハンミ ファーム． シーオー．， エルティーディー． 癌細胞成長抑制用新規アミド誘導体
JP2014513706A (ja) 2011-05-17 2014-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒを標的とする癌の組み合わせ治療方法
JP2014516082A (ja) 2011-06-07 2014-07-07 ハンミ ファーム． シーオー．， エルティーディー． ガン細胞の増殖を阻害するアミド誘導体および非金属塩滑沢剤を含む医薬組成物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えｃｔｌａ４ポリペプチドおよびその製造方法
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5869245A (en) 1996-06-05 1999-02-09 Fox Chase Cancer Center Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7935500B2 (en) 2002-03-26 2011-05-03 Massachusetts Institute Of Technology Identifying calcineurin activators for treatment of schizophrenia
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PL3053932T3 (pl) 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
RU2016107426A (ru) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
US20180057603A1 (en) * 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
JP6782698B2 (ja) * 2014-12-12 2020-11-11 セルキュイティー インコーポレイテッド がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法
JP2018504418A (ja) * 2015-02-05 2018-02-15 ティルノーヴォ リミテッド 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ
MA46852A (fr) * 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
KR20190054826A (ko) * 2017-11-14 2019-05-22 한미약품 주식회사 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도
CN113271948B (zh) * 2018-12-21 2024-08-16 得克萨斯大学体系董事会 治疗癌症的联合疗法
WO2020136417A2 (en) * 2018-12-27 2020-07-02 Pratik Sharma Manoeuvring subsystem of unmanned aerial vehicle

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529115A (ja) 2007-06-05 2010-08-26 ハンミ ファーム． シーオー．， エルティーディー． 癌細胞成長抑制用新規アミド誘導体
JP2014513706A (ja) 2011-05-17 2014-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒを標的とする癌の組み合わせ治療方法
JP2014516082A (ja) 2011-06-07 2014-07-07 ハンミ ファーム． シーオー．， エルティーディー． ガン細胞の増殖を阻害するアミド誘導体および非金属塩滑沢剤を含む医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Discovery，2013年，Vol.3, No.2，pp.224-237
Int. J. Cancer，2012年，Vol.130，pp.2445-2454

Also Published As

Publication number Publication date
CN112088000A (zh) 2020-12-15
MX2020010121A (es) 2021-01-08
RU2020134932A (ru) 2022-04-27
US20210361655A1 (en) 2021-11-25
KR102899689B1 (ko) 2025-12-12
EP3773551B1 (en) 2024-10-16
AU2019243738A1 (en) 2020-10-08
WO2019191279A3 (en) 2019-11-07
AU2019243738B2 (en) 2024-05-30
KR20200136417A (ko) 2020-12-07
WO2019191279A2 (en) 2019-10-03
CA3094108A1 (en) 2019-10-03
IL277373A (en) 2020-11-30
PH12020551495A1 (en) 2021-09-01
JP2021519306A (ja) 2021-08-10
EP3773551A2 (en) 2021-02-17
BR112020019251A2 (pt) 2021-01-12
SG11202009498RA (en) 2020-10-29
EP3773551A4 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
JP7685550B2 (ja) Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物
JP7709384B2 (ja) チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがんに対する化合物
JP7822597B2 (ja) チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがん細胞に対する抗腫瘍活性を有する化合物
KR102899689B1 (ko) Her2 엑손 19 돌연변이를 보유하는 암 세포에 대해 항 종양 활성을 갖는 화합물
CN113271948B (zh) 治疗癌症的联合疗法
HK40037136A (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
HK40064296A (en) Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
HK40013571B (zh) 具有针对携带egfr或her2外显子20突变之癌细胞的抗肿瘤活性的化合物
EA041212B1 (ru) Соединения с противоопухолевой активностью в отношении раковых клеток, несущих мутации в 20 экзоне egfr или her2

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220324

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231113

R150 Certificate of patent or registration of utility model

Ref document number: 7386174

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150